[A20-02] Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76
Last updated 20.03.2020
Commission awarded on 06.01.2020 by the Federal Joint Committee (G-BA).
Adults treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to major bleeding
Conclusion of dossier assessment A19-76 unchanged: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.